{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:54:27Z","timestamp":1793055267473,"version":"4.5.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A transmembrane protein that is extensively expressed, CD47 has an important role in the senescence of cancer cells. Therapy-induced senescence (TIS) by chemotherapy and radiotherapy restrains tumor proliferation yet drives immune evasion and treatment resistance, where CD47 acts as a core regulatory molecule linking cellular senescence and tumor immune escape. In this mini-review, we summarize the mechanisms governing CD47 upregulation during TIS, ranging from DNA damage response signaling, metabolic reprogramming and epigenetic modulation to post-transcriptional RNA modification. After addressing how CD47 is upregulated in TIS, we summarized the function of CD47 in both the maintaining the senescent statue and preventing senescent escape. Three major pathways are addressed. TSP-1\/CD47 axis functions as both senescence maintenance and preventing escape, while, p16\/c-MYC\/CD47 axis and CD47\/QPCT axis are responsible for senescence maintenance. Moreover, we summarize the therapeutic strategies toward CD47 blockade as s senolytic way, pointing out a novel strategy for oncotherapy. Overall, CD47 is a pivotal molecular bridge between TIS and immune tolerance. Future research on the role CD47 of cancer senescence, especially after chemotherapy or radiotherapy, could provide novel insight for oncotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1815122","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:17Z","timestamp":1784612177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting CD47-mediated cancer senescence, a novel strategy for cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Bei","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sichuan Academy of Medical Science and Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlu","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Academy of Medical Science and Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailian","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]},{"name":"Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Academy of Medical Science and Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Academy of Medical Science and Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12943-025-02475-8","article-title":"The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy","volume":"24","author":"Cao","year":"2025","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2020-lb-005","article-title":"Senescence in cancer","volume":"43","author":"Colucci","year":"2025","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16381","article-title":"The role of cellular senescence and SASP in tumour microenvironment","volume":"290","author":"Takasugi","year":"2023","journal-title":"FEBS J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12943-024-02096-7","article-title":"Cellular senescence and SASP in tumor progression and therapeutic opportunities","volume":"23","author":"Dong","year":"2024","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1772","article-title":"Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes","volume":"14","author":"Xiong","year":"2024","journal-title":"Clin Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202406.0057.v1","article-title":"Therapy-induced cellular senescence: potentiating tumor elimination or driving cancer resistance and recurrence","volume":"13","author":"Liu","year":"2024","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12943-025-02419-2","article-title":"Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics","volume":"24","author":"Feng","year":"2025","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10522-025-10370-4","article-title":"CD47 signaling in aging and age-related diseases: mechanisms, challenges, and therapeutic opportunities","volume":"27","author":"Mutombo Menga","year":"2025","journal-title":"Biogerontology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRPalpha axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2025071","article-title":"CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion","volume":"57","author":"Yuan","year":"2025","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7554\/elife.73677","article-title":"CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals","volume":"11","author":"Li","year":"2022","journal-title":"Elife"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","article-title":"Is CD47 an innate immune checkpoint for tumor evasion","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B15","volume-title":"Novel therapeutic strategies that interfere with senescence escape for the treatment of drug resistance in colorectal and breast cancer","author":"Jatal","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02321-5","article-title":"Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer","volume":"26","author":"Weng","year":"2025","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-024-02073-0","article-title":"The CD47\/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research","volume":"23","author":"Moniot","year":"2024","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091220","article-title":"The multifaceted p21 (Cip1\/Waf1\/CDKN1A) in cell differentiation, migration and cancer therapy","volume":"11","author":"Kreis","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101475","article-title":"The role of the cyclin dependent kinase inhibitor p21(cip1\/waf1) in targeting cancer: molecular mechanisms and novel therapeutics","volume":"11","author":"Al Bitar","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043436","article-title":"The potential of senescence as a target for developing anticancer therapy","volume":"24","author":"Jo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.02.30","article-title":"Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy","volume":"9","author":"Huang","year":"2017","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102717","article-title":"Anti-tumor strategies by harnessing the phagocytosis of macrophages","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41419-019-1406-7","article-title":"Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment","volume":"10","author":"Guillon","year":"2019","journal-title":"Cell Death Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2023.207.1_meetingabstracts.a2682","article-title":"Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT\/L axis","volume":"222","author":"Schloesser","year":"2023","journal-title":"J Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.155","article-title":"Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5582792","article-title":"Positively correlated CD47 activation and autophagy in umbilical cord blood-derived mesenchymal stem cells during senescence","volume":"2021","author":"Kim","year":"2021","journal-title":"Stem Cells Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2025147","article-title":"CD47 blockade enhances cisplatin sensitivity by inhibiting DNA repair gene expression","volume":"58","author":"Liu","year":"2025","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112677","article-title":"CD47 blockade enhances therapeutic efficacy of cisplatin against lung carcinoma in a murine model","volume":"405","author":"Cui","year":"2021","journal-title":"Exp Cell Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/gs-24-400","article-title":"Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer","volume":"13","author":"Zhao","year":"2024","journal-title":"Gland Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216727","article-title":"Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma","volume":"588","author":"Song","year":"2024","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s42003-023-04615-6","article-title":"The DNA damage response pathway regulates the expression of the immune checkpoint CD47","volume":"6","author":"Ghantous","year":"2023","journal-title":"Commun Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216605","article-title":"AMPK-mediated CD47 H3K4 methylation promotes phagocytosis evasion of glioma stem cells post-radiotherapy","volume":"583","author":"Sun","year":"2024","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1038\/s41467-022-34064-4","article-title":"Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","article-title":"Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02945-2","article-title":"RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC","volume":"132","author":"Zhang","year":"2025","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1524304","DOI":"10.3389\/fimmu.2025.1524304","article-title":"TSP-1-CD47-integrin alpha4beta1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis","volume":"16","author":"Hu","year":"2025","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaj1784","article-title":"The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1","volume":"10","author":"Meijles","year":"2017","journal-title":"Sci Signal"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004712","article-title":"Targeting the CD47\/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response","volume":"10","author":"Stirling","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci67465","article-title":"Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors","volume":"123","author":"Baek","year":"2013","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2024.03.002","article-title":"RAS-activated PI3K\/AKT signaling sustains cellular senescence via P53\/P21 axis in experimental models of psoriasis","volume":"115","author":"Mercurio","year":"2024","journal-title":"J Dermatol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08357-w","article-title":"Roles of TSP1-CD47 signaling pathway in senescence of endothelial cells: cell cycle, inflammation and metabolism","volume":"50","author":"Zhao","year":"2023","journal-title":"Mol Biol Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111952","article-title":"Blockade of TSP-1\/CD47 signal axis promotes donor hematopoietic engraftment by improving SEC\/MK niche function","volume":"28","author":"Wang","year":"2025","journal-title":"iScience"},{"key":"B44","article-title":"CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells","volume":"35","author":"Boukhari","year":"2015","journal-title":"Anticancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16547","article-title":"CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600069103","article-title":"Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a)","volume":"103","author":"Guney","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084062","article-title":"Thrombospondin-1 CD47 signalling: from mechanisms to medicine","volume":"22","author":"Kale","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910215","article-title":"Increased CD47 and MHC class I inhibitory signals expression in senescent CD1 primary mouse lung fibroblasts","volume":"22","author":"Hernandez-Mercado","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41514-024-00138-4","article-title":"Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment","volume":"10","author":"Lelarge","year":"2024","journal-title":"NPJ Aging"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.11.003","article-title":"The development of small-molecule inhibitors targeting CD47","volume":"26","author":"Yu","year":"2021","journal-title":"Drug Discov Today"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.135.2.533","article-title":"Thrombospondin modulates alpha v beta 3 function through integrin-associated protein","volume":"135","author":"Gao","year":"1996","journal-title":"J Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.12.3346","article-title":"C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chain-associated signaling pathway and by agglutination","volume":"98","author":"Tulasne","year":"2001","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m206849200","article-title":"Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion","volume":"277","author":"Barazi","year":"2002","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098358","article-title":"CD47-independent effects mediated by the TSP-derived 4N1K peptide","volume":"9","author":"Leclair","year":"2014","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14310","article-title":"Peptide analogues PKHB1 and 4N1K induce cell death through CD47-independent mechanisms","volume":"111","author":"Leclair","year":"2020","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121618","article-title":"Sphingomyelin nanosystems decorated with TSP-1 derived peptide targeting senescent cells","volume":"617","author":"Jatal","year":"2022","journal-title":"Int J Pharm"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRPalpha pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-024-10114-w","article-title":"Inhibitory immune checkpoints suppress the surveillance of senescent cells promoting their accumulation with aging and in age-related diseases","volume":"25","author":"Salminen","year":"2024","journal-title":"Biogerontology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-0037-t","article-title":"CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy","volume":"74","author":"Soto-Pantoja","year":"2014","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0367","article-title":"Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment","volume":"7","author":"Nath","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02397-7","article-title":"Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation","volume":"68","author":"Schwartz","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2111909","article-title":"Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice","volume":"11","author":"Nath","year":"2022","journal-title":"Oncoimmunology"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-02989-2","article-title":"Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody","volume":"71","author":"Ni","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-018-4884-x","article-title":"Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy","volume":"172","author":"Feliz-Mosquea","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B65","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/hon.3009","article-title":"Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-023-04710-6","article-title":"Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile","volume":"22","author":"Wang","year":"2024","journal-title":"J Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13989","article-title":"PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer","volume":"12","author":"Yang","year":"2021","journal-title":"Thorac Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00418-4","article-title":"Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition","volume":"7","author":"Al-Sudani","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-024-02982-4","article-title":"Targeting HDAC6 improves anti-CD47 immunotherapy","volume":"43","author":"Gracia-Hernandez","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027235","article-title":"Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data","volume":"13","author":"Son","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.36401\/jipo-21-x2","article-title":"Targeting CD47\/SIRPalpha in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab","volume":"4","author":"Haddad","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2092853","article-title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and\/or refractory acute myeloid leukemia","volume":"63","author":"Daver","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026849118","article-title":"Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance","volume":"118","author":"Upton","year":"2021","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:19Z","timestamp":1784612179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1815122"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815122","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1815122"}}